Kirstie L McDermott1, Nancy Fisher2, Sandra Bradford3, Richard Camicioli1. 1. Neuroscience and Mental Health Institute,University of Alberta,Edmonton,Canada. 2. Department of Psychiatry,University of Alberta,Edmonton,Canada. 3. Neuropsychology Clinic,University of Alberta,Edmonton,Canada.
Abstract
BACKGROUND: We apply recently recommended Parkinson's disease mild cognitive impairment (PD-MCI) classification criteria from the movement disorders society (MDS) to PD patients and controls and compare diagnoses to that of short global cognitive scales at baseline and over time. We also examine baseline prevalence of neuropsychiatric symptoms across different definitions of MCI. METHODS: 51 PD patients and 50 controls were classified as cognitively normal, MCI, or demented using MDS criteria (1.5 or 2.0 SD below normative values), Clinical Dementia Rating Scale (CDR), and the Dementia Rating Scale (DRS). All subject had parallel assessment with the Neuropsychiatric inventory (NPI). RESULTS: We confirmed that PD-MCI (a) is frequent, (b) increases the risk of PDD, and (c) affects multiple cognitive domains. We highlight the predictive variability of different criteria, suggesting the need for further refinement and standardization. When a common dementia outcome was used, the Level II MDS optimal testing battery with impairment defined as two SD below norms in 2+ tests performs the best. Neuropsychiatric symptoms were more common in PD across all baseline and longitudinal cognitive classifications. CONCLUSIONS: Our results advance previous findings on the utility of MDS PD-MCI criteria for PD patients and controls at baseline and over time. Additionally, we emphasize the possible utility of other cognitive scales and neuropsychiatric symptoms.
BACKGROUND: We apply recently recommended Parkinson's disease mild cognitive impairment (PD-MCI) classification criteria from the movement disorders society (MDS) to PDpatients and controls and compare diagnoses to that of short global cognitive scales at baseline and over time. We also examine baseline prevalence of neuropsychiatric symptoms across different definitions of MCI. METHODS: 51 PDpatients and 50 controls were classified as cognitively normal, MCI, or demented using MDS criteria (1.5 or 2.0 SD below normative values), Clinical Dementia Rating Scale (CDR), and the Dementia Rating Scale (DRS). All subject had parallel assessment with the Neuropsychiatric inventory (NPI). RESULTS: We confirmed that PD-MCI (a) is frequent, (b) increases the risk of PDD, and (c) affects multiple cognitive domains. We highlight the predictive variability of different criteria, suggesting the need for further refinement and standardization. When a common dementia outcome was used, the Level II MDS optimal testing battery with impairment defined as two SD below norms in 2+ tests performs the best. Neuropsychiatric symptoms were more common in PD across all baseline and longitudinal cognitive classifications. CONCLUSIONS: Our results advance previous findings on the utility of MDS PD-MCI criteria for PDpatients and controls at baseline and over time. Additionally, we emphasize the possible utility of other cognitive scales and neuropsychiatric symptoms.
Authors: Seok Jong Chung; Han Soo Yoo; Yang Hyun Lee; Hye Sun Lee; Byoung Seok Ye; Young H Sohn; Hunki Kwon; Phil Hyu Lee Journal: Hum Brain Mapp Date: 2019-05-14 Impact factor: 5.038
Authors: Lauren E Kenney; Adrianna M Ratajska; Francesca V Lopez; Catherine C Price; Melissa J Armstrong; Dawn Bowers Journal: Brain Sci Date: 2021-12-30